Internal Medicine, Medical Oncology · San Diego, CA
NPI
1942599915
Since 2011
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
200 W Arbor Dr
San Diego, CA, 92103
Phone (800) 926-8273
Groups this clinician bills Medicare through
Medicare paid, 2024
$970K
55,158 services
Medicare patients, 2024
326
Average age 74
Drug cost, 2024
$1.1M
689 prescriptions
Company payments, 2025
$48K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kelly E McCann was code J0897 (injection, denosumab, 1 mg), 3,601 times for 17 patients. In total Kelly E McCann billed 55,158 services in 115 codes, and Medicare paid $970K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,601 | 17 | $20.69 | $75K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 592 | 19 | $0.09 | $53.45 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 528 | 12 | $0.07 | $39.4 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 234 | 117 | $13.54 | $3,168 |
| 99215 Office E&M - Established | Office | 174 | 45 | $146.77 | $26K |
| 99214 Office E&M - Established | Office | 162 | 105 | $98.24 | $16K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 146 | 36 | $0.51 | $75.03 |
| 99233 Hospital E&M - Subsequent | Facility | 143 | 39 | $85.25 | $12K |
| 85025 Blood Count | Office | 137 | 70 | $7.61 | $1,043 |
| 96375 Injection Administration | Office | 136 | 26 | $13.80 | $1,876 |
| 96367 Intravenous Infusion, Hydration | Office | 110 | 24 | $25.64 | $2,821 |
| 96372 Injection Administration | Office | 109 | 48 | $11.55 | $1,259 |
| 96413 Chemotherapy Administration | Office | 109 | 33 | $117.88 | $13K |
| 96365 Intravenous Infusion, Hydration | Office | 79 | 39 | $54.35 | $4,294 |
| 96366 Intravenous Infusion, Hydration | Office | 79 | 17 | $17.95 | $1,418 |
By year: 2022 $711K for 44,559 services; 2023 $838K for 44,416 services; 2024 $970K for 55,158 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 137 | 70 | $7.61 | $1,043 |
| 36415 Venipuncture Blood Collection | 20 | 17 | $8.65 | $173 |
Medicare prescription drug claims, 2024
In 2024, the drug Kelly E McCann prescribed most often to Medicare patients was Letrozole, with 147 prescriptions and refills. In total Kelly E McCann wrote 689 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 147 | 428 | 48 | $4,684 |
| Tamoxifen Citrate Generic | 134 | 360 | 40 | $3,721 |
| Anastrozole Generic | 62 | 182 | 19 | $1,266 |
| Gabapentin Generic | 30 | 85 | 12 | $676 |
| Exemestane Generic | 27 | 73 | 13 | $3,278 |
| Ibrance Palbociclib | 26 | 26 | Under 11 | $418K |
| Ondansetron Hcl Generic | 26 | 30 | Under 11 | $569 |
| Prochlorperazine Maleate Generic | 19 | 19 | Under 11 | $160 |
| Tukysa Tucatinib | 19 | 19 | Under 11 | $486K |
| Olanzapine Generic | 14 | 18 | Under 11 | $474 |
| Alendronate Sodium Generic | 14 | 39 | Under 11 | $83.92 |
| Hydroxyurea Generic | 13 | 13 | Under 11 | $251 |
| Minoxidil Generic | 12 | 12 | Under 11 | $60.12 |
| Trazodone Hcl Generic | 11 | 15 | Under 11 | $21.39 |
| Escitalopram Oxalate Generic | 11 | 33 | Under 11 | $295 |
Brand drugs: 79 claims; generic drugs: 610 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kelly E McCann $48K ($48K in general payments such as food, travel and fees) from 13 companies. The largest payer was Lilly USA, LLC with $21K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 15 | $21K |
| Pfizer Inc. PFE | 5 | $9,161 |
| TerSera Therapeutics LLC | 9 | $3,684 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $3,352 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $2,799 |
| Puma Biotechnology, Inc. PBYI | 4 | $2,690 |
| Stemline Therapeutics Inc. | 16 | $2,096 |
| Merck Sharp & Dohme LLC MRK | 4 | $1,405 |
| Gilead Sciences, Inc. GILD | 4 | $941 |
| Genentech USA, Inc. ROG.SW | 1 | $123 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.